LEADER 02506nam 2200577z- 450 001 9910688446603321 005 20211118 035 $a(CKB)5400000000042738 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/72966 035 $a(oapen)doab72966 035 $a(EXLCZ)995400000000042738 100 $a20202111d2019 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aIntegrative Computational Systems Biology Approaches in Immunology and Medicine 210 $cFrontiers Media SA$d2019 215 $a1 online resource (290 p.) 311 08$a2-88945-801-6 330 $aThis eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact 606 $aMedical microbiology & virology$2bicssc 606 $aMicrobiology (non-medical)$2bicssc 606 $aScience: general issues$2bicssc 610 $aimmunology 610 $ainfections 610 $amathematical modeling 610 $amultiscale modeling 610 $asystems biolgoy 615 7$aMedical microbiology & virology 615 7$aMicrobiology (non-medical) 615 7$aScience: general issues 700 $aKaderali$b Lars$4edt$01351680 702 $aTheis$b Fabian$4edt 702 $aHernandez-Vargas$b Esteban A$4edt 702 $aGanusov$b Vitaly V$4edt 702 $aCiupe$b Stanca M$4edt 702 $aMehr$b Ramit$4edt 702 $aRibeiro$b Ruy$4edt 702 $aKaderali$b Lars$4oth 702 $aTheis$b Fabian$4oth 702 $aHernandez-Vargas$b Esteban A$4oth 702 $aGanusov$b Vitaly V$4oth 702 $aCiupe$b Stanca M$4oth 702 $aMehr$b Ramit$4oth 702 $aRibeiro$b Ruy$4oth 906 $aBOOK 912 $a9910688446603321 996 $aIntegrative Computational Systems Biology Approaches in Immunology and Medicine$93127342 997 $aUNINA LEADER 04515nam 2200481z- 450 001 9910346746503321 005 20210211 035 $a(CKB)4920000000094249 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/51977 035 $a(oapen)doab51977 035 $a(EXLCZ)994920000000094249 100 $a20202102d2018 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aLong-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models 210 $cFrontiers Media SA$d2018 215 $a1 online resource (201 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88945-530-0 330 $aThe purpose of this collection is to provide a forum to integrate pre-clinical and clinical investigations regarding the long-term consequences of adolescent exposure to drugs of abuse. Adolescence is characterized by numerous behavioral and biological changes, including substantial neurodevelopment. Behaviorally, adolescents are more likely to engage in risky activities and make impulsive decisions. As such, the majority of substance use begins in adolescence, and an earlier age of onset of use (<15 yr) is strongly associated with the risk for developing a substance use disorder later in life. Furthermore, adolescent drug use may negatively impact ongoing neurological development, which could lead to long-term cognitive and emotional deficits. A large number of clinical studies have investigated both the acute and long-term effects of adolescent drug use on functional outcomes. However, the clinical literature contains many conflicting findings, and is often hampered by the inability to know if functional differences existed prior to drug use. Moreover, in human populations it is often very difficult to control for the numerous types of drugs, doses, and combinations used, not to mention the many other environmental factors that may influence adult behavior. Therefore, an increase in the number of carefully controlled studies using relevant animal models has the potential to clarify which adolescent experiences, particularly what drugs used when, have long-term negative consequences. Despite the advantages of animal model systems in clarifying these issues, the majority of pre-clinical addiction research over the past 50+ years has been conducted in adult animals. Moreover, few addiction-related studies have investigated the long-term neurocognitive consequences of drug exposure at any age. In the past 10 years of so, however, the field of adolescent drug abuse research has burgeoned. To date, the majority of this research has focused on adolescent alcohol exposure using a variety of animal models. The results have given the field important insight into why adolescents are more likely to drink alcohol to excess relative to adults, and the danger of adolescent alcohol use (e.g., in leading to a persistence of excessive drinking in adulthood). More recently, research regarding the effects of adolescent exposure to other drugs of abuse, including nicotine, cocaine, and cannabinoids has expanded. Therefore, we are at unique point in time, when emerging results from carefully controlled pre-clinical studies can inform the sometimes confusing clinical literature. In addition, we expect an influx of prospective clinical studies in response to a cross-institute initiative at NIH, known as the ABCD grant. Several institutes are enrolling children prior to adolescence (and the initiation of drug use), in order to control for pre-existing neurobiological and neurobehavioral differences and to monitor the age of initiation and amount of drug used more carefully than is possible using retrospective designs. 517 $aLong-Term Consequences of Adolescent Drug Use 606 $aMedicine$2bicssc 610 $aalcohol 610 $acannabinoid 610 $acocaine 610 $ajuvenile 610 $aketamine 610 $amethamphetamine 610 $anicotine 610 $aprefrontal cortex 610 $asex differences 610 $astress 615 7$aMedicine 700 $aTorregrossa$b Mary$4auth$01831309 702 $aBarker$b Jacqueline M$4auth 702 $aGourley$b Shannon L$4auth 906 $aBOOK 912 $a9910346746503321 996 $aLong-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models$94403478 997 $aUNINA